OTCPK:HALB - Post by User
Post by
badgirl007on Aug 12, 2021 8:52am
134 Views
Post# 33690700
01 - Listing of Halberd Corp. on Canadian stock exchange!
01 - Listing of Halberd Corp. on Canadian stock exchange! Listing on one of Canada's stock exchanges and continued success in research with terrific interim results will finally put Halberd Corp. where they belong: To the top league!
STOCK PERFORMANCE
Because of the reallocation of research efforts described above, stock performance during the second quarter trended downward. Now that we have solidified our focus on non-transient medical conditions, will be launching our Vita-Shield-Max™ immune support product, anticipate up listing to the OTCQB index and are petitioning for listing on a Canadian exchange, we believe the negative factors impacting our stock price in the second quarter should be removed.
Q3 OBJECTIVES
- Establish proof-of concept for eradication of E. Coli via RF and laser as a first step towards development of a treatment for Alzheimer’s Disease.
- Conduct laboratory experimentation on the effectiveness of a new concept for the extracorporeal capture and removal of disease antigens without the need for metallic nanoparticles. (Details to be provided pending patent application filings).
- Launch immune support product to the market.
- Complete application for up listing HALB to OTCQB index.
- Complete application for Halberd Corp.’s listing on one of the Canadian stock exchanges.
- Continue issuing press releases at the rate of 4-6/mo.
Since Halberd is a small company, we must compete in areas in which the large companies have not been successful, or could not venture due to our intellectual property. Our strong position on extracorporeal treatment of disease as well as the unfulfilled need for effective treatments for Alzheimer’s Disease (AD) and many other diseases made our decision mandatory. Application of Halberd’s patented technology required development of proprietary antibodies and the conjugation of metallic nanoparticles to facilitate eradication of disease antigens via radio frequency (RF) and lasers. Due to ASU’s and GreenBioAZ’s expertise in developing and conjugating antibodies with metallic nanoparticles, Halberd decided to capitalize on their talents to develop treatments for AD and other diseases. https://halberdcorporation.com/halberd-corporation-ceo-letter-2/